Consolidated sales of the Ceva Group reached EUR424 million (US$462 million) at the end of June 2015, representing growth of 16 percent and a 12 percent increase at constant perimeter and exchange rates.
Sales grew in all zones, except Europe which was stable versus the same period of 2014, with strong performance in North America/Pacific region (up 43 percent), Asia (up 38 percent) and Latin America (up 26 percent).
Business centered around all species are growing, especially poultry (up 27 percent globally and up 35 percent on vaccines) and companion animals (up 13 percent).
The group delivered an operational result slightly ahead of the budgeted objective and continued to make significant investment in research and development.
Marc Prikazsky, Ceva’s chairman and CEO commented: “The growth of the group remains consistent and ahead of our 2020 business plan. It’s very pleasing to see that our previous investment to develop innovative new technology vaccines is being rewarded with increased business from our poultry customers. We have a significant new pipeline of products to launch, which will further boost our business in companion animals, swine and dairy. ”
